Acute Leukemia

With vitro proliferation assay in Ba/F3 cells, it was found that the cells bearing FLT3-ITD Y693C/N exhibited >10-fold resistance to Gilteritinib. Similar resistance was found in cells bearing FLT3-IT… (full text at CIViC)

PMID 32040554 · Tarver et al., 2020 · Open in CIViC

The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib a… (full text at CIViC)

PMID 22858906 · Williams et al., 2013 · Open in CIViC

A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC)

PMID 22858906 · Williams et al., 2013 · Open in CIViC

Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC)

PMID 15667533 · Smith et al., 2005 · Open in CIViC

FOXP1-ABL1 fusion was identified in Ph-like ALL

PMID 31935290 · Harvey et al., 2020 · Open in CIViC

This study investigates the diagnostic importance of the translocation t(16;21)(p11;q22), resulting in the TLS/FUS::ERG fusion gene, in acute myeloid leukemia (AML). The authors utilized RT-PCR to det… (full text at CIViC)

PMID 9242552 · Kong et al., 1997 · Open in CIViC

This international retrospective study investigates the diagnostic features of acute myeloid leukemia (AML) with the t(16;21) translocation resulting in the FUS::ERG fusion gene in pediatric patients.… (full text at CIViC)

PMID 30150206 · Noort et al., 2018 · Open in CIViC

Children with Down syndrome are at increased risk to developing Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia associated with Down Syndrome (ML-DS). GATA1, a gene that encodes an essentia… (full text at CIViC)

PMID 27069254 · Arber et al., 2016 · Open in CIViC

We report an additional case of twin-to-twin transmission of a TAM clone with identical GATA1 exon 2 mutations in monochorionic-diamniotic twin infants without constitutional T21. This case along with… (full text at CIViC)

PMID 32464589 · Roseman et al., 2020 · Open in CIViC

GATA2 ZF1 mutations are associated with distinct clinico-biological features and predict better prognosis, different from zinc finger 1 mutations, in AML patients. ZF1 mutations were closely associate… (full text at CIViC)

PMID 30190467 · Tien et al., 2018 · Open in CIViC

I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%.

PMID 29860938 · DiNardo et al., 2018 · Open in CIViC

Phase 3 trial of 146 patients randomized to either IDH1 inhibitor ivosidenib and azacitidine or azacitidine and placebo revealed significantly longer event-free survival in the ivosidenib-group. Patie… (full text at CIViC)

PMID 35443108 · Montesinos et al., 2022 · Open in CIViC

Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.

PMID 20805365 · Schnittger et al., 2010 · Open in CIViC

In this post hoc long-term follow-up of the phase 3 AGILE trial (NCT03173248; median follow-up 28.6 months; n=148), IDH1 R132 mutations served as the obligate driver alteration defining patient eligib… (full text at CIViC)

PMID 40706052 · Montesinos et al., 2025 · Open in CIViC

In the phase 3 AGILE trial enrolling patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction chemotherapy, IDH1 R132 mutations (confirmed by FDA-approved Abbott Real… (full text at CIViC)

PMID 35443108 · Montesinos et al., 2022 · Open in CIViC

IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation.

PMID 20538800 · Abbas et al., 2010 · Open in CIViC

IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.

PMID 20538800 · Abbas et al., 2010 · Open in CIViC

Popovici-Muller et al. report that IDH1 R132 mutations are gain-of-function alterations that result in production of the oncometabolite D-2-hydroxyglutarate (2-HG). The authors state that elevated 2-H… (full text at CIViC)

PMID 29670690 · Popovici-Muller et al., 2018 · Open in CIViC

Popovici-Muller et al. reported preliminary efficacy data from an ongoing phase 1 study of ivosidenib (AG-120) monotherapy in patients with IDH1-mutated malignancies. In patients with relapsed or refr… (full text at CIViC)

PMID 29670690 · Popovici-Muller et al., 2018 · Open in CIViC

In a multicenter phase I dose-escalation and expansion study, 125 patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) received ivosidenib 500 mg once daily. The complete rem… (full text at CIViC)

PMID 29860938 · DiNardo et al., 2018 · Open in CIViC

In a final five-year analysis of a multicenter phase 2 trial, 35 patients with relapsed/refractory IDH1 R132H-mutated acute myeloid leukemia (AML) received olutasidenib monotherapy. The overall respo… (full text at CIViC)

PMID 41239466 · Cortes et al., 2025 · Open in CIViC

In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced c… (full text at CIViC)

PMID 25583779 · 2015 · Open in CIViC

In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced c… (full text at CIViC)

PMID 25583779 · 2015 · Open in CIViC

In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival.

PMID 20421455 · Thol et al., 2010 · Open in CIViC

A first-in-human phase 1/2 trial assessing the pharmacology, safety and activity of Enasidenib in IDH2-mutant myeloid hematoblastosis patients. In the AML subgroup (n=176, (n=130 R140; n=45 R172; n=1 … (full text at CIViC)

PMID 28588020 · Stein et al., 2017 · Open in CIViC

In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2.

PMID 21596855 · Green et al., 2011 · Open in CIViC

In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2.

PMID 22616558 · Zhou et al., 2012 · Open in CIViC